Last reviewed 2026-04-23 · How we verify

Oxaliplatin for injection

Oxaliplatin works by interfering with DNA replication in cancer cells, leading to cell death.

Oxaliplatin works by interfering with DNA replication in cancer cells, leading to cell death. Used for Adjuvant treatment of stage III colon cancer, First-line treatment of metastatic colorectal cancer.

At a glance

Mechanism of action

Oxaliplatin is a platinum-based chemotherapy drug that forms platinum-DNA adducts, which prevent DNA replication and transcription, ultimately causing cell death in rapidly dividing cancer cells. This mechanism is particularly effective against colorectal cancer cells.

Approved indications

• Adjuvant treatment of stage III colon cancer
• First-line treatment of metastatic colorectal cancer

Common side effects

• Neurotoxicity
• Myelosuppression
• Gastrointestinal toxicity

Key clinical trials

• HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer (NA)
• A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. (PHASE1)
• Retlirafusp Alfa Injection Combined Chemotherapy for Perioperative Treatment of Esophagogastric Junction Adenocarcinoma: A Single-Arm, Phase II Study of Safety and Efficacy (NA)
• Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer (PHASE2)
• A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs (PHASE3)
• Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (PHASE2)
• Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) (PHASE1, PHASE2)
• Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.